GW Pharmaceuticals

Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sleep, Monitor Deloitte, Growth, Patient, Acquisition, Cancer, Spacecraft, Senior, Therapy, Bain, Partner, GW Pharmaceuticals, ADC, Bain & Company, Corporate development, Jazz Pharmaceuticals, Pharmaceutical industry

Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).

Key Points: 
  • Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).
  • “I am delighted to welcome George to the Mythic team,” said Brian Fiske, Ph.D., Chief Scientific Officer and Co-Founder at Mythic Therapeutics.
  • Prior to that, Dr. Eliades spent over 20 years at Bain & Company and Monitor Group, advising biotech clients in corporate strategy, M&A, growth and digital-driven transformations.
  • Dr. Eliades stated, “I’m incredibly excited to join Mythic and work toward improving outcomes for more cancer patients through our pipeline of innovative ADCs.

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
Thursday, March 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover

Retrieved on: 
Tuesday, August 8, 2023
Temple University, Drug discovery, Head, University of Bristol, Merck, Commercial Operating System, Biotechnology Innovation Organization, Otsuka Pharmaceutical, BIO, University, Ōtsuka, GW, Honours degree, GW Pharmaceuticals, Genetic distance, Corcept Therapeutics, Organization, UCB, Villalba v Merrill Lynch & Co Inc, Cannabidiol, Mazda North American Operations, Drexel University, Epilepsy, Neuroscience, INSEAD, Justin, Roivant Sciences, Therapy, Doctor of Philosophy, Sale, Defense Innovation Board, DSM-IV codes, Jazz Pharmaceuticals, University of Edinburgh, Pharmaceutical industry, Xenon

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover.
  • Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “On behalf of our Board of Directors, I am delighted to welcome Gillian and Justin to our Board.
  • Gillian brings a vast knowledge of commercializing novel medicines and leading successful neuroscience franchises at large pharmaceutical companies.
  • Mr. Gover currently serves on the Board of Directors for CURE Epilepsy and Rady Children’s Institute for Genomic Medicine.

OMass Therapeutics Expands Leadership Team with Two New Appointments

Retrieved on: 
Wednesday, August 2, 2023
CASE, GSK, UCL, Royal college, Central nervous system, University, University of London, OSI Pharmaceuticals, Senior, Oxford, Biotechnology, Pharmacognosy, University of Cambridge, ARC, Drug, GW Pharmaceuticals, Royal London Hospital, Internal medicine, Biology, AstraZeneca, Manchester Metropolitan University, Psoriasis, Development, UCB, Shire (pharmaceutical company), Weapon Shop de Omasse, Novartis, DMPK, Toxicology, Imperial College London, MRCP, NHS, Rare, Therapy, Membership of the Royal Colleges of Physicians of the United Kingdom, Safety, Barts and The London School of Medicine and Dentistry, Management, Pharmaceutical industry, Pharmacology, Pfizer

Peter Phillips M.D., Ph.D. has joined as Senior Vice President of Clinical Development and Julia Sampson Ph.D. as Vice President of Non-clinical Development.

Key Points: 
  • Peter Phillips M.D., Ph.D. has joined as Senior Vice President of Clinical Development and Julia Sampson Ph.D. as Vice President of Non-clinical Development.
  • “Both Peter and Julia have a huge amount of experience in taking programs from preclinical through to clinical development and I am hugely excited about what they will bring to the OMass team,” said Ros Deegan, CEO of OMass Therapeutics.
  • “With our solid financial backing and new expanded facilities, we are growing our team strategically as we advance our pipeline of exciting early-stage assets in immunology and rare diseases.
  • In her most recent role at Kalvista Pharmaceuticals, she was responsible for strategy, leadership, recruitment and management of the non-clinical safety assessment team, leading toxicology, safety pharmacology and DMPK functions.

MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

Retrieved on: 
Tuesday, May 2, 2023
Biotechnology, General Health, Mental Health, Health, Pharmaceutical, FOR, PFE, DRS, Patent Cooperation Treaty, Annual general meeting, Acquisition, Patient, Patent, Investment, Risk, Financial management, NYSE, FCM, GAD, GW Pharmaceuticals, Research, DSM-IV codes, Aerie Pharmaceuticals, FDA, Mental health, Social media, NOT, ALC, ALL, Annual Meetings of the International Monetary Fund and the World Bank Group, Multimedia, LSD, Trustee, NEO, MindMed, Drug development, SG, Spectrum, Clinical trial, Pfizer, Celgene, RBC Capital Markets, Invention, Jazz Pharmaceuticals, EF Hutton, Psychiatry, Management, Auction, Security (finance), Pharmaceutical industry, Medical device, Alcon, ADHD

The Company has launched www.ProtectMindMed.com to keep shareholders up to date on key developments leading up to the Annual Meeting.

Key Points: 
  • The Company has launched www.ProtectMindMed.com to keep shareholders up to date on key developments leading up to the Annual Meeting.
  • The full text of the Board’s letter to shareholders, which can be viewed and downloaded here , follows:
    Thank you for your investment in MindMed.
  • Your vote at the Company’s 2023 Annual General Meeting of Shareholders, scheduled for June 15, 2023, is critically important this year.
  • Shareholders will receive proxy materials directly via the preferred method, hard copy or email, specific to each shareholder’s account.

MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, LLP, Chairperson, Medicine, Annual Meetings of the International Monetary Fund and the World Bank Group, GW Pharmaceuticals, Bristol Myers Squibb, Celgene, BMY, NYSE, Cooley LLP, Acquisition, Alcon, Aerie Pharmaceuticals, Patient, Hoskin, Annual general meeting, Our Boarding House, CFO, Jazz Pharmaceuticals, Growth, NEO, MindMed, FCM, Pharmaceutical industry, Management

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has filed its preliminary proxy materials with the U.S. Securities and Exchange Commission (“SEC”) in connection with the 2023 Annual General Meeting of Shareholders (the “Annual Meeting”), which has not yet been scheduled.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has filed its preliminary proxy materials with the U.S. Securities and Exchange Commission (“SEC”) in connection with the 2023 Annual General Meeting of Shareholders (the “Annual Meeting”), which has not yet been scheduled.
  • In the preliminary proxy statement, MindMed sets forth its highly qualified slate of candidates for election to the Company’s Board of Directors (the “Board”) at the Annual Meeting.
  • He currently serves as a board member at Seagen Inc. (NASDAQ: SGEN) and Forte Biosciences, Inc. (NASDAQ: FBRX).
  • The Company looks forward to continuing to communicate with shareholders as our Annual Meeting approaches.

Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors

Retrieved on: 
Wednesday, April 12, 2023
Amgen, Executive, Epilepsy, IMPL, GW Pharmaceuticals, Prescription, Seagen, Organization, Acquisition, Patient, Jazz Pharmaceuticals, Commercial, Therapy, Pharmaceutical industry, Management, Dihydroergotamine, Impeller

SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors.

Key Points: 
  • SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors.
  • The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately.
  • "It is my pleasure to welcome Darren to the Impel Board of Directors,” said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals.
  • Mr. Cline currently serves on the board of directors of Pliant Therapeutics and Pyxis Oncology.

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

Retrieved on: 
Wednesday, March 8, 2023
Epilepsy, Science, Amgen, MBA, Fibrosis, Growth, Jan Vansina, Seagen, Marketing, Acquisition, Novartis, Commercial, Therapy, Jazz Pharmaceuticals, San Diego State University, GW Pharmaceuticals, ASGE, Acceleron Pharma, SAN, Executive, University, Madison, Chief commercial officer, Journal of Pharmacy and Pharmacology, Ironwood Pharmaceuticals, Pharmacology, Ironwood, Pepperdine University, Pharmaceutical industry, Management, Pharmacy

SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointments of Darren Cline and Thomas McCourt to its Board of Directors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointments of Darren Cline and Thomas McCourt to its Board of Directors.
  • "I am pleased to welcome Darren and Thomas whose extensive commercial and operational expertise will be crucial as we progress toward late-stage clinical development,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics.
  • Mr. Cline currently serves as Chief Executive Officer and President of Epygenix Therapeutics, a clinical stage company developing therapies for rare epilepsies.
  • Mr. Cline currently serves on the board of directors of Pyxis Oncology.

Aadi Bioscience Announces Leadership Transition

Retrieved on: 
Friday, March 3, 2023
GW Pharmaceuticals, TSC2, Allergan, AADI, Perivascular epithelioid cell tumour, CFO, Interim, Aadi, Acquisition, Jazz Pharmaceuticals, TSC1, Executive, Patient, Management

Scott Giacobello, currently the Company's Chief Financial Officer, has been appointed to serve as Interim Chief Executive Officer and President in addition to his current responsibilities.

Key Points: 
  • Scott Giacobello, currently the Company's Chief Financial Officer, has been appointed to serve as Interim Chief Executive Officer and President in addition to his current responsibilities.
  • In addition, Neil Desai, Ph.D., the Founder of Aadi Bioscience and its President and CEO prior to Mr. Delaney, continues to serve as the Executive Chairman and a member of the Board of directors and will assist with the leadership transition.
  • Mr. Giacobello said, "I look forward to my continued work with the Aadi board and management team, executing on our mission of developing FYARRO for significant unmet needs in oncology.
  • Prior to joining Aadi in 2021, Mr. Giacobello's background included fulfilling key financial and operational roles with a long history of leadership in commercial stage growth companies.

Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England

Retrieved on: 
Tuesday, January 31, 2023
Newton, Dravet syndrome, Tuberous sclerosis, TSA, Heart, Jazz Pharmaceuticals, EMA, GW, Strategic planning, Medicines and Healthcare products Regulatory Agency, Seizure, NHS, Medicine, Skin, TSC, Epilepsy, Lennox–Gastaut syndrome, Cannabidiol, NICE, Wales, GW Pharmaceuticals, Brain, MHRA, Patient, National Institute for Health and Care Excellence, Ann Mercy Hunt, Clobazam, Healthcare Improvement Scotland, European Medicines Agency, Pharmaceutical industry

TSC can be diagnosed in infancy but many children are not diagnosed until later in childhood when their seizures begin and other symptoms appear.

Key Points: 
  • TSC can be diagnosed in infancy but many children are not diagnosed until later in childhood when their seizures begin and other symptoms appear.
  • [4] It is estimated that between 3,700 and 11,000 people in the UK live with TSC.
  • TSC is a very difficult to manage condition, with common issues including epilepsy in eight out of ten people.
  • Please note that, in relation to this Jazz media announcement, no honorarium was provided to the Tuberous Sclerosis Association.